Akero Historical Balance Sheet

AKRO Stock

USD 32.73 1.53 4.90%

Trend analysis of Akero Therapeutics balance sheet accounts such as Other Current Liab of 9.4 M, Total Current Liabilities of 13.9 M or Total Stockholder Equity of 562.1 M provides information on Akero Therapeutics' total assets, liabilities, and equity, which is the actual value of Akero Therapeutics to its prevalent stockholders. By breaking down trends over time using Akero Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Akero Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Akero Therapeutics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

About Akero Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Akero Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Akero Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Akero Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Akero currently owns. An asset can also be divided into two categories, current and non-current.

Akero Therapeutics Balance Sheet Chart

At this time, Akero Therapeutics' Short Term Investments are very stable compared to the past year. As of the 22nd of November 2024, Liabilities And Stockholders Equity is likely to grow to about 609.3 M, while Other Current Liabilities is likely to drop about 9.4 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Total Permanent Equity Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Akero Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Akero Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Akero Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Akero Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Akero Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Akero Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Akero Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Akero Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.At this time, Akero Therapeutics' Short Term Investments are very stable compared to the past year. As of the 22nd of November 2024, Liabilities And Stockholders Equity is likely to grow to about 609.3 M, while Other Current Liabilities is likely to drop about 9.4 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	18.2M	10.8M	11.6M	9.4M
Total Assets	195.5M	356.6M	580.3M	609.3M

Other Current Liab Total Assets

Akero Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Capital Surpluse	Non Current Liabilities Other	Short Long Term Debt Total	Property Plant And Equipment Net	Net Receivables	Capital Lease Obligations
Total Assets		0.74	0.79	0.99	0.96	-0.91	-0.98	0.82	0.87	0.89	0.11	0.12	1.0	0.75	0.08	0.81	0.28	0.99	1.0	1.0	0.88	0.33	0.91	-0.93	0.79	-0.91
Other Current Liab	0.74		0.99	0.74	0.81	-0.87	-0.81	0.89	0.87	0.47	0.71	0.73	0.74	0.57	-0.11	0.95	0.16	0.73	0.74	0.73	0.86	0.71	0.46	-0.65	0.81	-0.71
Total Current Liabilities	0.79	0.99		0.78	0.85	-0.9	-0.87	0.95	0.91	0.51	0.66	0.67	0.79	0.67	-0.06	0.98	0.22	0.78	0.79	0.78	0.92	0.72	0.53	-0.73	0.87	-0.77
Total Stockholder Equity	0.99	0.74	0.78		0.98	-0.89	-0.97	0.81	0.85	0.88	0.12	0.13	0.99	0.76	-0.06	0.8	0.14	1.0	0.99	0.99	0.89	0.34	0.9	-0.92	0.79	-0.91
Net Tangible Assets	0.96	0.81	0.85	0.98		-0.94	-0.96	0.86	0.91	0.77	0.23	0.26	0.97	0.74	-0.12	0.85	0.1	0.98	0.97	0.96	0.93	0.5	0.81	-0.88	0.79	-0.87
Net Debt	-0.91	-0.87	-0.9	-0.89	-0.94		0.92	-0.89	-0.98	-0.62	-0.35	-0.38	-0.91	-0.6	-0.1	-0.87	-0.33	-0.88	-0.91	-0.91	-0.92	-0.61	-0.67	0.78	-0.76	0.79
Retained Earnings	-0.98	-0.81	-0.87	-0.97	-0.96	0.92		-0.91	-0.9	-0.83	-0.24	-0.24	-0.98	-0.79	-0.08	-0.89	-0.3	-0.97	-0.98	-0.98	-0.92	-0.42	-0.87	0.95	-0.89	0.95
Accounts Payable	0.82	0.89	0.95	0.81	0.86	-0.89	-0.91		0.92	0.55	0.53	0.52	0.83	0.8	0.05	0.96	0.3	0.8	0.83	0.81	0.95	0.7	0.62	-0.83	0.94	-0.84
Cash	0.87	0.87	0.91	0.85	0.91	-0.98	-0.9	0.92		0.56	0.37	0.41	0.88	0.64	0.1	0.89	0.34	0.84	0.88	0.87	0.95	0.64	0.62	-0.76	0.78	-0.75
Non Current Assets Total	0.89	0.47	0.51	0.88	0.77	-0.62	-0.83	0.55	0.56		-0.14	-0.15	0.88	0.71	0.08	0.59	0.2	0.89	0.88	0.89	0.63	-0.07	0.97	-0.88	0.66	-0.84
Non Currrent Assets Other	0.11	0.71	0.66	0.12	0.23	-0.35	-0.24	0.53	0.37	-0.14		0.99	0.12	0.21	-0.17	0.62	0.02	0.11	0.12	0.1	0.36	0.81	-0.2	-0.06	0.41	-0.19
Other Assets	0.12	0.73	0.67	0.13	0.26	-0.38	-0.24	0.52	0.41	-0.15	0.99		0.13	0.16	-0.19	0.62	0.0	0.12	0.13	0.11	0.37	0.83	-0.22	-0.04	0.37	-0.16
Cash And Short Term Investments	1.0	0.74	0.79	0.99	0.97	-0.91	-0.98	0.83	0.88	0.88	0.12	0.13		0.75	0.08	0.82	0.28	0.99	1.0	1.0	0.89	0.34	0.9	-0.93	0.79	-0.91
Common Stock Shares Outstanding	0.75	0.57	0.67	0.76	0.74	-0.6	-0.79	0.8	0.64	0.71	0.21	0.16	0.75		-0.08	0.79	0.1	0.77	0.75	0.75	0.82	0.37	0.74	-0.85	0.87	-0.78
Non Current Liabilities Total	0.08	-0.11	-0.06	-0.06	-0.12	-0.1	-0.08	0.05	0.1	0.08	-0.17	-0.19	0.08	-0.08		-0.01	0.96	-0.06	0.08	0.09	-0.06	-0.17	0.09	-0.05	0.0	-0.02
Other Current Assets	0.81	0.95	0.98	0.8	0.85	-0.87	-0.89	0.96	0.89	0.59	0.62	0.62	0.82	0.79	-0.01		0.26	0.8	0.82	0.8	0.93	0.69	0.59	-0.78	0.91	-0.79
Total Liab	0.28	0.16	0.22	0.14	0.1	-0.33	-0.3	0.3	0.34	0.2	0.02	0.0	0.28	0.1	0.96	0.26		0.14	0.28	0.28	0.19	0.04	0.21	-0.24	0.23	-0.22
Net Invested Capital	0.99	0.73	0.78	1.0	0.98	-0.88	-0.97	0.8	0.84	0.89	0.11	0.12	0.99	0.77	-0.06	0.8	0.14		0.99	0.99	0.88	0.32	0.91	-0.93	0.79	-0.91
Total Current Assets	1.0	0.74	0.79	0.99	0.97	-0.91	-0.98	0.83	0.88	0.88	0.12	0.13	1.0	0.75	0.08	0.82	0.28	0.99		1.0	0.88	0.34	0.9	-0.93	0.79	-0.91
Net Working Capital	1.0	0.73	0.78	0.99	0.96	-0.91	-0.98	0.81	0.87	0.89	0.1	0.11	1.0	0.75	0.09	0.8	0.28	0.99	1.0		0.88	0.32	0.91	-0.93	0.78	-0.91
Capital Surpluse	0.88	0.86	0.92	0.89	0.93	-0.92	-0.92	0.95	0.95	0.63	0.36	0.37	0.89	0.82	-0.06	0.93	0.19	0.88	0.88	0.88		0.6	0.69	-0.85	0.89	-0.81
Non Current Liabilities Other	0.33	0.71	0.72	0.34	0.5	-0.61	-0.42	0.7	0.64	-0.07	0.81	0.83	0.34	0.37	-0.17	0.69	0.04	0.32	0.34	0.32	0.6		-0.03	-0.22	0.47	-0.31
Short Long Term Debt Total	0.91	0.46	0.53	0.9	0.81	-0.67	-0.87	0.62	0.62	0.97	-0.2	-0.22	0.9	0.74	0.09	0.59	0.21	0.91	0.9	0.91	0.69	-0.03		-0.94	0.71	-0.9
Property Plant And Equipment Net	-0.93	-0.65	-0.73	-0.92	-0.88	0.78	0.95	-0.83	-0.76	-0.88	-0.06	-0.04	-0.93	-0.85	-0.05	-0.78	-0.24	-0.93	-0.93	-0.93	-0.85	-0.22	-0.94		-0.9	0.97
Net Receivables	0.79	0.81	0.87	0.79	0.79	-0.76	-0.89	0.94	0.78	0.66	0.41	0.37	0.79	0.87	0.0	0.91	0.23	0.79	0.79	0.78	0.89	0.47	0.71	-0.9		-0.89
Capital Lease Obligations	-0.91	-0.71	-0.77	-0.91	-0.87	0.79	0.95	-0.84	-0.75	-0.84	-0.19	-0.16	-0.91	-0.78	-0.02	-0.79	-0.22	-0.91	-0.91	-0.91	-0.81	-0.31	-0.9	0.97	-0.89

Click cells to compare fundamentals

Akero Therapeutics Account Relationship Matchups

Akero Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	138.1M	273.3M	195.5M	356.6M	580.3M	609.3M
Other Current Liab	8.4M	9.4M	18.2M	10.8M	11.6M	9.4M
Total Current Liabilities	9.4M	13.1M	25.1M	19.1M	19.1M	13.9M
Total Stockholder Equity	128.7M	258.7M	169.1M	326.6M	535.3M	562.1M
Net Tangible Assets	128.7M	258.7M	169.1M	326.6M	375.5M	394.3M
Net Debt	(136.4M)	(185.4M)	(149.0M)	(238.8M)	(207.9M)	(218.3M)
Retained Earnings	(130.3M)	(209.5M)	(310.3M)	(422.3M)	(574.1M)	(545.4M)
Accounts Payable	947K	3.4M	6.7M	8.0M	7.0M	4.3M
Cash	136.4M	187.2M	150.5M	249.8M	234.2M	162.6M
Non Current Assets Total	69K	2.0M	2.0M	1.4M	20.3M	21.3M
Non Currrent Assets Other	29K	161K	417K	108K	(1.0)	(0.95)
Other Assets	69K	201K	417K	108K	1.0	0.95
Cash And Short Term Investments	136.4M	268.4M	188.3M	351.4M	550.0M	577.5M
Common Stock Shares Outstanding	15.1M	31.5M	34.8M	39.0M	52.6M	34.6M
Short Term Investments	71.6M	81.1M	37.8M	101.7M	315.8M	331.6M
Liabilities And Stockholders Equity	138.1M	273.3M	195.5M	356.6M	580.3M	609.3M
Non Current Liabilities Total	23K	1.5M	1.3M	10.9M	25.8M	19.4M
Other Current Assets	1.6M	5.9M	10.6M	7.4M	10.0M	5.8M
Other Stockholder Equity	120.9M	468.2M	479.4M	748.9M	1.1B	1.2B
Total Liab	9.4M	14.6M	26.4M	30.0M	45.0M	29.5M
Net Invested Capital	128.7M	258.7M	169.1M	336.1M	560.3M	588.3M
Total Current Assets	138.0M	271.3M	193.6M	355.2M	560.0M	588.0M
Accumulated Other Comprehensive Income	(6K)	(3K)	(27K)	37K	270K	283.5K
Net Working Capital	128.7M	258.2M	168.5M	336.1M	540.8M	567.9M
Capital Surpluse	259.0M	468.2M	479.4M	748.9M	861.2M	438.3M

Pair Trading with Akero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Akero Stock

0.79	MTEM	Molecular Templates	Pair Corr
0.78	NKTX	Nkarta Inc	Pair Corr
0.76	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.69	TPST	Tempest Therapeutics	Pair Corr
0.68	VALN	Valneva SE ADR	Pair Corr

The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.

The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:

How To Invest In Akero

Details

Is Akero Stock a good investment?

Details

What is Akero Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.78)

Return On Assets

(0.23)

Return On Equity

(0.36)

The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Akero Historical Balance Sheet

About Akero Balance Sheet Analysis

Akero Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Akero Therapeutics balance sheet Correlations

Akero Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akero Therapeutics balance sheet Accounts

Pair Trading with Akero Therapeutics

Moving against Akero Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments

Net Working Capital	- 0.98	Retained Earnings
Total Current Assets	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Assets
Net Invested Capital	- 0.97	Retained Earnings